C9 and myeloid sarcoma: As shown in Table 2, two proteins, complement C9 and cytochrome P450 family 24 subfamily A member 1 (CYP24A1), were significantly different between MS cases and healthy controls, after multiple testing Holm correction, and thus they were considered as potential biomarkers.